PDF(Pubmed)
Abstract：
UNASSIGNED: We report a case of metastatic human epidermal growth factor receptor-2 (HER2) positive breast cancer who achieved encouraging clinical benefits across multiple pyrotinib-based anti-HER2 therapies.
UNASSIGNED: A 33-year-old woman was diagnosed with hormone receptor (HR) positive, HER2-positive breast cancer in June 2018, and did not receive adjuvant radiotherapy, chemotherapy, or anti-HER2 targeted therapy post-breast conserving surgery. By May 2020, she developed recurrence of the left breast mass with metastases in liver, bone and lymph nodes. She then received pyrotinib plus trastuzumab and nab-paclitaxel as first-line therapy. Both the left breast mass and liver metastases showed noticeable improvement, with the disease evaluated as partial response (PR). Despite this promising result, the patient developed brain metastases after first-line treatment. A combination regimen of pyrotinib retention plus inetetamab and vinorelbine were administered as second-line anti-HER2 therapy, and the brain metastases visibly shrunk, leading to PR, with the extracranial lesions remaining stable. Ultimately, due to brain lesions progression, the treatment was transitioned to trastuzumab deruxtecan. We applied next generation sequencing (NGS) to illustrate the efficacy of anti-HER2 therapy and minimal residual disease (MRD) to detect the disease status.
UNASSIGNED: Pyrotinib is a promising antineoplastic agent for HER2-positive advanced breast cancer patients. Under the guidance of precision medicine, it is encouraged to utilize novel diagnostic and therapeutic methods to manage advanced breast cancer patients.
UNASSIGNED: A 33-year-old woman was diagnosed with hormone receptor (HR) positive, HER2-positive breast cancer in June 2018, and did not receive adjuvant radiotherapy, chemotherapy, or anti-HER2 targeted therapy post-breast conserving surgery. By May 2020, she developed recurrence of the left breast mass with metastases in liver, bone and lymph nodes. She then received pyrotinib plus trastuzumab and nab-paclitaxel as first-line therapy. Both the left breast mass and liver metastases showed noticeable improvement, with the disease evaluated as partial response (PR). Despite this promising result, the patient developed brain metastases after first-line treatment. A combination regimen of pyrotinib retention plus inetetamab and vinorelbine were administered as second-line anti-HER2 therapy, and the brain metastases visibly shrunk, leading to PR, with the extracranial lesions remaining stable. Ultimately, due to brain lesions progression, the treatment was transitioned to trastuzumab deruxtecan. We applied next generation sequencing (NGS) to illustrate the efficacy of anti-HER2 therapy and minimal residual disease (MRD) to detect the disease status.
UNASSIGNED: Pyrotinib is a promising antineoplastic agent for HER2-positive advanced breast cancer patients. Under the guidance of precision medicine, it is encouraged to utilize novel diagnostic and therapeutic methods to manage advanced breast cancer patients.
摘要：
■我们报告了一例转移性人表皮生长因子受体-2（HER2）阳性乳腺癌，该患者在多种基于吡唑替尼的抗HER2治疗中获得了令人鼓舞的临床益处。
■一名33岁女性被诊断为激素受体（HR）阳性，2018年6月HER2阳性乳腺癌，未接受辅助放疗，化疗,或抗HER2靶向治疗保乳手术后。到2020年5月，她出现了左乳腺肿块复发，肝脏转移，骨和淋巴结。然后，她接受了pyrotinib联合曲妥珠单抗和nab-紫杉醇作为一线治疗。左乳腺肿块和肝转移均有明显改善，该疾病被评估为部分反应（PR）。尽管结果很有希望，患者在一线治疗后出现脑转移.作为二线抗HER2治疗，给予吡唑替尼保留联合依奈他单抗和长春瑞滨的联合方案，脑转移明显缩小，导致PR,颅外病变保持稳定。最终,由于脑部病变进展，治疗转用曲妥珠单抗deruxtecan.我们应用下一代测序（NGS）来说明抗HER2治疗的功效和微小残留病（MRD）来检测疾病状态。
■吡罗替尼是HER2阳性晚期乳腺癌患者的一种有前途的抗肿瘤药物。在精准医学的指导下,鼓励利用新的诊断和治疗方法来管理晚期乳腺癌患者。
■一名33岁女性被诊断为激素受体（HR）阳性，2018年6月HER2阳性乳腺癌，未接受辅助放疗，化疗,或抗HER2靶向治疗保乳手术后。到2020年5月，她出现了左乳腺肿块复发，肝脏转移，骨和淋巴结。然后，她接受了pyrotinib联合曲妥珠单抗和nab-紫杉醇作为一线治疗。左乳腺肿块和肝转移均有明显改善，该疾病被评估为部分反应（PR）。尽管结果很有希望，患者在一线治疗后出现脑转移.作为二线抗HER2治疗，给予吡唑替尼保留联合依奈他单抗和长春瑞滨的联合方案，脑转移明显缩小，导致PR,颅外病变保持稳定。最终,由于脑部病变进展，治疗转用曲妥珠单抗deruxtecan.我们应用下一代测序（NGS）来说明抗HER2治疗的功效和微小残留病（MRD）来检测疾病状态。
■吡罗替尼是HER2阳性晚期乳腺癌患者的一种有前途的抗肿瘤药物。在精准医学的指导下,鼓励利用新的诊断和治疗方法来管理晚期乳腺癌患者。
